e fully digitalized and/or be given a diuretic, and the response observed closely. if cardiac failure continues, despite adequate digitalization and diuretic, pindolol therapy should be withdrawn (gradually, if possible). exacerbation of ischemic heart disease following abrupt withdrawal hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abrupt discontinuation of such therapy. when discontinuing chronically administered pindolol, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1 to 2 weeks and the patient should be carefully monitored. if angina markedly worsens or acute coronary insufficiency develops, pindolol administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. patients should be other measures appropriate for the management of unstable angina should be taken. patients should be warned against interruption or discontinuation of therapy without the physician's advice. because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue pindolol therapy abruptly even in patients treated only for hypertension. nonallergic bronchospasm (e.g., chronic bronchitis, emphysema) - patients with bronchospastic diseases should in general not receive beta-blockers pindolol should be administered with caution since it may block bronchodilation produced by endogenous or exogenous catecholamine stimulation of beta 2 receptors. major surgery because beta-blockade impairs the ability of the heart to respond to reflex stimuli and may increase the risks of general anesthesia and surgical procedures, resulting in protracted hypotension or low cardiac output, it has generally been suggested that such therapy should be gradually withdrawn several days prior to surgery. recognition of the increased sensitivity to catecholamines of patients recently withdrawn from beta-blocker therapy, however, has made this recommendation controversial. if possible, beta-blockers should be withdrawn well before surgery takes place. in the event of emergency surgery, the anesthesiologist should be informed that the patient is on beta-blocker therapy. the effects of pindolol can be reversed by administration of beta-receptor agonists such as isoproterenol, dopamine, dobutamine, or norepinephrine. difficulty in restarting and maintaining the heart beat has also been reported with beta-adrenergic receptor blocking agents. diabetes and hypoglycemia beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., tachycardia and blood pressure changes) of acute hypoglycemia. this is especially important with labile diabetics. beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. thyrotoxicosis beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-blockade which might precipitate a thyroid crisis.

s: patients received either propranolol, α-methyldopa or a diuretic (hydrochlorothiazide or chlorthalidone). pindolol body system / ( n = 322 ) adverse reactions % central nervous system bizarre or many dreams 5 dizziness 9 fatigue 8 hallucinations <1 insomnia 10 nervousness 7 weakness 4 autonomic nervous system paresthesia 3 cardiovascular dyspenea 5 edema 6 heart failure <1 palpitations <1 musculoskeletal chest pain 3 joint pain 7 muscle cramps 3 muscle pain 10 gastrointestinal abdominal discomfort 4 nausea 5 skin pruritus 1 rash <1 active controls * body system / ( n = 188 ) adverse reactions % central nervous system bizarre or many dreams 0 dizziness 11 fatigue 4 hallucinations 0 insomnia 3 nervousness 3 weakness 2 autonomic nervous system paresthesia 2 cardiovascular dyspenea 4 edema 3 heart failure <1 palpitations 1 musculoskeletal chest pain 1 joint pain 4 muscle cramps 1 muscle pain 9 gastrointestinal abdominal discomfort 4 nausea 2 skin pruritus <1 rash <1 placebo body system / ( n = 78 ) adverse reactions % central nervous system bizarre or many dreams 6 dizziness 1 fatigue 4 hallucinations 0 insomnia 10 nervousness 5 weakness 1 autonomic nervous system paresthesia 6 cardiovascular dyspenea 6 edema 1 heart failure 0 palpitations 0 musculoskeletal chest pain 3 joint pain 4 muscle cramps 0 muscle pain 8 gastrointestinal abdominal discomfort 5 nausea 1 skin pruritus 0 rash 1 the following selected (potentially important) adverse reactions were seen in 2% or fewer patients and their relationship to pindolol is uncertain. central nervous system: anxiety, lethargy; autonomic nervous system: visual disturbances, hyperhidrosis; cardiovascular: bradycardia, claudication, cold extremities, heart block, hypotension, syncope, tachycardia, weight gain; gastrointestinal: diarrhea, vomiting; respiratory: wheezing; urogenital: impotence, pollakiuria; miscellaneous: eye discomfort or burning eyes. potential adverse effects in addition, other adverse effects not aforementioned have been reported with other beta-adrenergic blocking agents and should be considered potential adverse effects of pindolol. central nervous system: reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics. cardiovascular: intensification of av block. (see contraindications .) allergic: erythematous rash; fever combined with aching and sore throat; laryngospasm; respiratory distress. hematologic: agranulocytosis; thrombocytopenic and nonthrombocytopenic purpura. gastrointestinal: mesenteric arterial thrombosis; ischemic colitis. miscellaneous: reversible alopecia; peyronie's disease. the oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with pindolol during investigational use and extensive foreign experience amounting to over 4 million patient-years.

nificance of this observation has not been evaluated and there is no evidence, or reason to believe, that exercise cardiac output is less affected by pindolol. pindolol has been shown in controlled, double-blind clinical studies to be an effective antihypertensive agent when used as monotherapy, or when added to therapy with thiazide-type diuretics. divided dosages in the range of 10 mg to 60 mg daily have been shown to be effective. as monotherapy, pindolol is as effective as propranolol, α-methyldopa, hydrochlorothiazide, and chlorthalidone in reducing systolic and diastolic blood pressure. the effect on blood pressure is not orthostatic, i.e., pindolol was equally effective in reducing the supine and standing blood pressure. in open, long-term studies up to 4 years, no evidence of diminution of the blood pressure lowering response was observed. an average 3-pound increase in body weight has been noted in patients treated with pindolol alone, a larger increase than was observed with propranolol or placebo. the weight gain appeared unrelated to blood pressure response and was not associated with an increased risk of heart failure, although edema was more common than in control patients. pindolol does not have a consistent effect on plasma renin activity. the mechanism of the antihypertensive effects of beta-blocking agents has not been established, but several mechanisms have been postulated: 1) an effect on the central nervous system resulting in a reduced sympathetic outflow to the periphery, 2) competitive antagonism of catecholamines at peripheral (especially cardiac) adrenergic receptor sites, leading to decreased cardiac output, 3) an inhibition of renin release. these mechanisms appear less likely for pindolol than other beta-blockers in view of the modest effect on resting cardiac output and renin. beta-blockade therapy is useful when it is necessary to suppress the effects of beta-adrenergic agonists in order to achieve therapeutic goals. however, in certain clinical situations, (e.g., cardiac failure, heart block, bronchospasm), the preservation of an adequate sympathetic tone may be necessary to maintain vital functions. although a beta-antagonist with isa such as pindolol does not eliminate sympathetic tone entirely, there is no controlled evidence that it is safer than other beta-blockers in such conditions as heart failure, heart block, or bronchospasm or is less likely to cause those conditions. in single-dose studies of the effects of beta-blockers on fev, pindolol was indistinguishable from other noncardioselective agents in its reduction of fev, and its reduction in the effectiveness of an exogenous beta-agonist. exacerbation of angina and, in some cases, myocardial infarction and ventricular dysrhythmias have been reported after abrupt discontinuation of therapy with beta-adrenergic blocking agents in patients with coronary artery disease. abrupt withdrawal of these agents in patients without coronary artery disease has resulted in transient symptoms, including tremulousness, sweating, palpitation, headache, and malaise. several mechanisms have been proposed to explain these phenomena, among them increased sensitivity to catecholamines because of increased numbers of beta receptors. pharmacokinetics and metabolism pindolol is rapidly and reproducibly absorbed (greater than 95%), achieving peak plasma concentrations within 1 hour of drug administration. pindolol has no significant first-pass effect. the blood concentrations are proportional in a linear manner to the administered dose in the range of 5 mg to 20 mg. upon repeated administration to the same subject, variation is minimal. after a single dose, intersubject variation for peak plasma concentrations was about 4-fold (e.g., 45 to 167 ng/ml for a 20 mg dose). upon multiple dosing, intersubject variation decreased to 2- to 2.5-fold. pindolol is only 40% bound to plasma proteins and is evenly distributed between plasma and red cells. the volume of distribution in healthy subjects is about 2 l/kg. pindolol undergoes extensive metabolism in animals and man. in man, 35% to 40% is excreted unchanged in the urine and 60% to 65% is metabolized primarily to hydroxy-metabolites which are excreted as glucuronides and ethereal sulfates. the polar metabolites are excreted with a half-life of approximately 8 hours and thus multiple dosing therapy (q.8h) results in a less than 50% accumulation in plasma. about 6% to 9% of an administered intravenous dose is excreted by the bile into the feces. the disposition of pindolol after oral administration is monophasic with a half-life in healthy subjects or hypertensive patients with normal renal function of approximately 3 to 4 hours. following t.i.d. administration (q.8h), no significant accumulation of pindolol is observed. in elderly hypertensive patients with normal renal function, the half-life of pindolol is more variable, averaging about 7 hours, but with values as high as 15 hours. in hypertensive patients with renal diseases, the half-life is within the range expected for healthy subjects. however, a significant decrease (50%) in volume of distribution (v d ) is observed in uremic patients and v d appears to be directly correlated to creatinine clearance. therefore, renal drug clearance is significantly reduced in uremic patients, resulting in a significant decrease in urinary excretion of unchanged drug. uremic patients with a creatinine clearance of less than 20 ml/min generally excreted less than 15% of the administered dose unchanged in the urine. in patients with histologically diagnosed cirrhosis of the liver, the elimination of pindolol was more variable in rate and generally significantly slower than in healthy subjects. the total body clearance of pindolol in cirrhotic patients ranged from about 50 to 300 ml/min and was directly correlated to antipyrine clearance. the half-life ranges from 2.5 hours to greater than 30 hours. these findings strongly suggest that caution should be exercised in dosage adjustments of pindolol in such patients. the bioavailability of pindolol is not significantly affected by coadministration of food, hydralazine, hydrochlorothiazide or aspirin. pindolol has no effect on warfarin activity or the clinical effectiveness of digoxin, although small transient decreases in plasma digoxin concentrations were noted.

healthcare limited matoda, ahmedabad, india. distributed by: zydus pharmaceuticals usa inc. pennington, nj 08534 rev.: 10/16